Harnessing the microbiome for cancer therapy

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• The microbiome plays a crucial role in cancer pathogenesis and response to therapy.
• Microbial communities and their metabolites impact drug metabolism, immune responses, and epigenetic alterations within the tumor microenvironment.
• The gut microbiome influences systemic and local cancer processes.

Purpose of the Study:

• To review the multifaceted role of the microbiome in cancer.
• To highlight microbiome-targeted interventions as potential adjuncts to conventional cancer treatments.
• To discuss the microbiome's potential as a biomarker and therapeutic target in oncology.

Main Methods:

• Literature review of current research on the microbiome in cancer.
• Analysis of studies investigating microbiome-targeted interventions (e.g., fecal microbiota transplantation, diet, prebiotics, probiotics).
• Discussion of emerging data on the microbiome's prognostic and predictive value.

Main Results:

• The microbiome influences cancer through local and systemic mechanisms, affecting drug metabolism and the immune landscape.
• Microbiome-targeted interventions show potential for enhancing efficacy and reducing toxicity of cancer therapies.
• The microbiome can serve as a prognostic and predictive biomarker in cancer care.

Conclusions:

• The microbiome is a promising therapeutic target and modifiable factor in cancer prevention and treatment.
• Further research is needed to address knowledge gaps and limitations in study designs.
• Mechanism-guided, personalized strategies are essential for advancing clinical translation of microbiome-based therapies.